Table 1.
Characteristics of studies included in the systematic review
| Trial | Country | Patients, n | Female (%) | Age, years | BMI, kg/m2 | Follow up (weeks) | Baseline for LDL-C(mg/dl) | Characteristics of patients | Dose of bempedoic acid |
|---|---|---|---|---|---|---|---|---|---|
| Ballantyne 2013 | US | 177 | 44.6 | 57.5 | 28.2 | 12 | 166.2 | No stain used | 40, 80, or 120 mg daily |
| Gutierrez 2014 | US | 60 | 38.3 | 55.7 | 29.9 | 12 | 126.8 | No stain used | 180 mg daily |
| Thompson 2015 | US | 56 | 50.0 | 63.5 | 29.7 | 12 | 179.05 | Statin intolerant | 120 mg, 180 mg, or 240 mg |
| Ballantyne 2016 | US | 133 | 59.4 | 57.3 | 30.3 | 12 | 135.6 | Stable statin background therapy | 180 mg daily |
| Thompson 2016 | US | 149 | 71.1 | 59.7 | 29.7 | 12 | 163.9 | With or without statin intolerant | 120 mg or 180 mg |
| Ballantyne 2018 | US | 269 | 61.3 | 63.8 | 29.8 | 12 | 127.6 | Statin intolerance | 180 mg daily |
| Laufs 2019 | Germany | 345 | 50.4 | 65.2 | 30.3 | 24 | 157.6 | Statin intolerance | 180 mg daily |
| Ray 2019 | UK | 2230 | 27.0 | 66.1 | NR | 52 | 103.2 | Maximally tolerated statin therapy | 180 mg daily |
| Ballantyne 2019 | US | 129 | 50.4 | 65.1 | 30.6 | 12 | 148.08 | Maximally tolerated statin therapy | 180 mg daily |
| Goldberg 2019 | US | 779 | 36.3 | 64.3 | 30.2 | 52 | 120.4 | Maximally tolerated statin therapy | 180 mg daily |
| Lalwani 2019 | US | 64 | 48.4 | 58.0 | 31.0 | 4 | 76.4 | High-intensity statin background therapy | 180 mg daily |
NR not reported, BMI body-mass index, LDL- low-density lipoprotein cholesterol